Abstract
COVID-19 is currently well known among the general population. The current pandemic treatment requires patient compliant, safe, tolerable, and orally effective. RNA dependent RNA polymerase (RdRp) is an important enzyme involved in RNA synthesis by the formation of phosphodiester bonds within the virus. Effective oral antiviral agents are urgently needed to treat, block transmission and prevent progression to severe illness in COVID-19. Molnupiravir is a orally active RdRp inhibitor. The Developmental steps of molnupiravir includes prophylactic efcacy in a ferret model and its therapeutic efcacy against COVID-19 patients has been proven.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
